S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:THTX

Theratechnologies (THTX) Stock Price, News & Analysis

$1.66
+0.20 (+13.70%)
(As of 03/28/2024 ET)
Today's Range
$1.45
$1.66
50-Day Range
$1.18
$2.03
52-Week Range
$0.88
$4.30
Volume
62,500 shs
Average Volume
75,015 shs
Market Capitalization
$40.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
THTX stock logo

About Theratechnologies Stock (NASDAQ:THTX)

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

THTX Stock Price History

THTX Stock News Headlines

Your $200 account credit is about to expire
Update to MarketBeat All Access and Save $300 on Your Annual Subscription
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
Theratechnologies: Fiscal Q4 Earnings Snapshot
Will This Dual-Listed Bio-Pharma Catch New Year Action?
FDA Approves Theratechnologies' Trogarzo 90-second IV Push Loading Dose
FDA Approves Theratechnologies' Trogarzo 90-second IV Push Loading Dose
See More Headlines
Receive THTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theratechnologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/21/2024
Today
3/28/2024
Next Earnings (Estimated)
4/10/2024
Fiscal Year End
11/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:THTX
Employees
103
Year Founded
1993

Profitability

Net Income
$-23,960,000.00
Pretax Margin
-28.78%

Debt

Sales & Book Value

Annual Sales
$81.76 million
Book Value
($0.86) per share

Miscellaneous

Free Float
N/A
Market Cap
$40.17 million
Optionable
Optionable
Beta
1.31

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Paul Lévesque (Age 59)
    President, CEO & Director
    Comp: $1.18M
  • Mr. Philippe Dubuc M.B.A. (Age 57)
    MBA, Senior VP & CFO
    Comp: $432.31k
  • Mr. Jocelyn Lafond L.L.M. (Age 56)
    LL.B., General Counsel & Corporate Secretary
    Comp: $316.29k
  • Dr. Christian Marsolais Ph.D. (Age 61)
    Senior VP & Chief Medical Officer
    Comp: $434.61k
  • Mr. John Leasure (Age 59)
    Global Commercial Officer
    Comp: $420.91k
  • Hon. Andre Dupras M.Sc. (Age 60)
    Vice President of Human Resources

THTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Theratechnologies stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Theratechnologies in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" THTX shares.
View THTX analyst ratings
or view top-rated stocks.

How have THTX shares performed in 2024?

Theratechnologies' stock was trading at $1.62 at the beginning of the year. Since then, THTX stock has increased by 2.5% and is now trading at $1.66.
View the best growth stocks for 2024 here
.

Are investors shorting Theratechnologies?

Theratechnologies saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 17,100 shares, a decline of 35.7% from the February 29th total of 26,600 shares. Based on an average daily trading volume, of 74,500 shares, the short-interest ratio is presently 0.2 days. Currently, 0.1% of the company's shares are short sold.
View Theratechnologies' Short Interest
.

When is Theratechnologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 10th 2024.
View our THTX earnings forecast
.

How were Theratechnologies' earnings last quarter?

Theratechnologies Inc. (NASDAQ:THTX) issued its quarterly earnings data on Wednesday, February, 21st. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.24) by $0.16. The business had revenue of $23.45 million for the quarter. During the same period in the previous year, the firm earned ($0.36) EPS.

When did Theratechnologies' stock split?

Shares of Theratechnologies reverse split on Monday, July 31st 2023. The 1-4 reverse split was announced on Monday, July 31st 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

What guidance has Theratechnologies issued on next quarter's earnings?

Theratechnologies issued an update on its FY 2024 earnings guidance on Wednesday, February, 21st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $87.0 million-$90.0 million, compared to the consensus revenue estimate of $91.4 million.

What other stocks do shareholders of Theratechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Theratechnologies investors own include Trevena (TRVN), Citius Pharmaceuticals (CTXR), Great Panther Mining (GPL), TherapeuticsMD (TXMD), Advanced Micro Devices (AMD), Bionano Genomics (BNGO), ChromaDex (CDXC), Caladrius Biosciences (CLBS) and Chimerix (CMRX).

Who are Theratechnologies' major shareholders?

Theratechnologies' stock is owned by a variety of institutional and retail investors. Top institutional investors include AIGH Capital Management LLC (15.37%), Nantahala Capital Management LLC (11.08%), Worth Venture Partners LLC (3.75%), National Bank of Canada FI (0.47%), Stifel Financial Corp (0.29%) and Wealthspire Advisors LLC (0.21%).

How do I buy shares of Theratechnologies?

Shares of THTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Theratechnologies have any subsidiaries?
The following companies are subsidiares of Theratechnologies: Katana, Pharma-G Inc., Theratechnologies Europe Inc., Theratechnologies Europe Limited, Theratechnologies Intercontinental Inc., and Theratechnologies U.S. Inc.
Read More
This page (NASDAQ:THTX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners